Estcourt MJ - Search Results

1

Innate immunity defines the capacity of antiviral T cells to limit persistent infection.

Andrews DM, Estcourt MJ, Andoniou CE, Wikstrom ME, Khong A, Voigt V, Fleming P, Tabarias H, Hill GR, van der Most RG, Scalzo AA, Smyth MJ, Degli-Esposti MA. Andrews DM, et al. Among authors: estcourt mj. J Exp Med. 2010 Jun 7;207(6):1333-43. doi: 10.1084/jem.20091193. Epub 2010 May 31. J Exp Med. 2010. PMID: 20513749 Free PMC article.

2

rAAV.sFlt-1 gene therapy achieves lasting reversal of retinal neovascularization in the absence of a strong immune response to the viral vector.

Lai CM, Estcourt MJ, Wikstrom M, Himbeck RP, Barnett NL, Brankov M, Tee LB, Dunlop SA, Degli-Esposti MA, Rakoczy EP. Lai CM, et al. Among authors: estcourt mj. Invest Ophthalmol Vis Sci. 2009 Sep;50(9):4279-87. doi: 10.1167/iovs.08-3253. Epub 2009 Apr 8. Invest Ophthalmol Vis Sci. 2009. PMID: 19357358

3

Preclinical safety evaluation of subretinal AAV2.sFlt-1 in non-human primates.

Lai CM, Estcourt MJ, Himbeck RP, Lee SY, Yew-San Yeo I, Luu C, Loh BK, Lee MW, Barathi A, Villano J, Ang CL, van der Most RG, Constable IJ, Dismuke D, Samulski RJ, Degli-Esposti MA, Rakoczy EP. Lai CM, et al. Among authors: estcourt mj. Gene Ther. 2012 Oct;19(10):999-1009. doi: 10.1038/gt.2011.169. Epub 2011 Nov 10. Gene Ther. 2012. PMID: 22071974

4

CpG pretreatment enhances antiviral T-cell immunity against cytomegalovirus.

Ong ML, Wikstrom ME, Fleming P, Estcourt MJ, Hertzog PJ, Hill GR, Andoniou CE, Degli-Esposti MA. Ong ML, et al. Among authors: estcourt mj. Blood. 2013 Jul 4;122(1):55-60. doi: 10.1182/blood-2012-12-471227. Epub 2013 May 14. Blood. 2013. PMID: 23673858 Free article.

5

TRAIL+ NK cells control CD4+ T cell responses during chronic viral infection to limit autoimmunity.

Schuster IS, Wikstrom ME, Brizard G, Coudert JD, Estcourt MJ, Manzur M, O'Reilly LA, Smyth MJ, Trapani JA, Hill GR, Andoniou CE, Degli-Esposti MA. Schuster IS, et al. Among authors: estcourt mj. Immunity. 2014 Oct 16;41(4):646-56. doi: 10.1016/j.immuni.2014.09.013. Immunity. 2014. PMID: 25367576 Free article.

6

Prime-boost immunization generates a high frequency, high-avidity CD8(+) cytotoxic T lymphocyte population.

Estcourt MJ, Ramsay AJ, Brooks A, Thomson SA, Medveckzy CJ, Ramshaw IA. Estcourt MJ, et al. Int Immunol. 2002 Jan;14(1):31-7. doi: 10.1093/intimm/14.1.31. Int Immunol. 2002. PMID: 11751749

7

DNA vaccines against human immunodeficiency virus type 1.

Estcourt MJ, McMichael AJ, Hanke T. Estcourt MJ, et al. Immunol Rev. 2004 Jun;199:144-55. doi: 10.1111/j.0105-2896.2004.00151.x. Immunol Rev. 2004. PMID: 15233732 Review.

8

Vaccine route, dose and type of delivery vector determine patterns of primary CD8+ T cell responses.

Estcourt MJ, Létourneau S, McMichael AJ, Hanke T. Estcourt MJ, et al. Eur J Immunol. 2005 Sep;35(9):2532-40. doi: 10.1002/eji.200535184. Eur J Immunol. 2005. PMID: 16144036 Free article.

9

Core protocol for the adaptive Platform Trial In COVID-19 Vaccine priming and BOOsting (PICOBOO).

McLeod C, Ramsay J, Flanagan KL, Plebanski M, Marshall H, Dymock M, Marsh J, Estcourt MJ, Wadia U, Williams PCM, Tjiam MC, Blyth C, Subbarao K, Nicholson S, Faust S, Thornton RB, Mckenzie A, Snelling TL, Richmond P. McLeod C, et al. Among authors: estcourt mj. Trials. 2023 Mar 18;24(1):202. doi: 10.1186/s13063-023-07225-z. Trials. 2023. PMID: 36934272 Free PMC article.

10

Altered primary CD8+ T cell response to a modified virus Ankara(MVA)-vectored vaccine in the absence of CD4+ T cell help.

Estcourt MJ, McMichael AJ, Hanke T. Estcourt MJ, et al. Eur J Immunol. 2005 Dec;35(12):3460-7. doi: 10.1002/eji.200526284. Eur J Immunol. 2005. PMID: 16245361 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

22 results

Search Page